MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Progyny Book Value 2011-2026 | PGNY
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Progyny
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 422 M | 553 M | 377 M | 252 M | 167 M | 114 M | 11.1 M | 10.7 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 553 M | 10.7 M | 238 M |
Quarterly Book Value Progyny
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 560 M | 515 M | 467 M | 422 M | 435 M | 456 M | - | 553 M | 515 M | 469 M | 424 M | 377 M | 347 M | - | 280 M | 252 M | 224 M | 205 M | 185 M | 167 M | 167 M | 167 M | 167 M | 114 M | 114 M | 114 M | 114 M | 11.1 M | 11.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 560 M | 11.1 M | 290 M |
Book Value of other stocks in the Health information services industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Accolade
ACCD
|
391 M | - | 0.29 % | $ 206 M |  USA |
 |
Cerner Corporation
CERN
|
3.68 B | - | - | $ 27.9 B | USA |
 |
HealthEquity
HQY
|
2.11 B | $ 82.4 | 0.45 % | $ 7.1 B | USA |
 |
Change Healthcare
CHNG
|
3.28 B | - | - | $ 9.03 B | USA |
 |
Computer Programs and Systems
CPSI
|
187 M | - | 4.4 % | $ 133 M | USA |
 |
iCAD
ICAD
|
28.7 M | - | - | $ 102 M | USA |
 |
Covetrus
CVET
|
1.53 B | - | - | $ 2.94 B | USA |
 |
Akerna Corp.
KERN
|
666 M | - | - | $ 161 M | USA |
 |
Castlight Health, Inc.
CSLT
|
7.25 B | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
715 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
26.4 M | - | - | $ 6.37 B | USA |
 |
Evolent Health
EVH
|
859 M | $ 3.75 | - | $ 351 M | USA |
 |
GoodRx Holdings
GDRX
|
725 M | $ 2.55 | 8.05 % | $ 984 M | USA |
 |
10x Genomics
TXG
|
741 M | $ 22.43 | 1.72 % | $ 2.63 B | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
1.41 B | - | -10.39 % | $ 886 M | USA |
 |
MTBC
MTBC
|
59.5 M | - | -0.58 % | $ 51.7 M | USA |
 |
1Life Healthcare
ONEM
|
1.73 B | - | - | $ 3.37 B | USA |
 |
Premier
PINC
|
1.53 B | - | - | $ 2.33 B | USA |
 |
NextGen Healthcare
NXGN
|
432 M | - | - | $ 1.6 B | USA |
 |
Health Catalyst
HCAT
|
246 M | $ 1.45 | 16.0 % | $ 101 M | USA |
 |
OptimizeRx Corporation
OPRX
|
127 M | $ 6.7 | 7.54 % | $ 115 M | USA |
 |
Schrödinger
SDGR
|
364 M | $ 12.39 | 3.6 % | $ 910 M | USA |
 |
Phreesia
PHR
|
337 M | $ 9.67 | 4.82 % | $ 578 M | USA |
 |
R1 RCM
RCM
|
347 M | - | - | $ 3.81 B | USA |
 |
Teladoc Health
TDOC
|
1.39 B | $ 6.46 | 6.6 % | $ 1.14 B | USA |
 |
Signify Health
SGFY
|
821 M | - | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
12.3 M | - | - | $ 21.4 M | USA |
 |
NantHealth
NH
|
-225 M | - | -46.64 % | $ 10.4 M | USA |
 |
SCWorx Corp.
WORX
|
7.15 M | - | - | $ 7.71 M | USA |
 |
American Well Corporation
AMWL
|
248 M | $ 6.12 | -3.16 % | $ 98.2 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
-57 M | - | - | $ 255 M | USA |
 |
HealthStream
HSTM
|
511 M | $ 20.72 | -0.19 % | $ 630 M | USA |
 |
Omnicell
OMCL
|
1.24 B | $ 42.8 | 3.33 % | $ 1.97 B | USA |
 |
So-Young International
SY
|
1.67 B | $ 3.0 | -0.66 % | $ 234 M |  China |
 |
Veeva Systems
VEEV
|
7.21 B | $ 171.6 | 10.02 % | $ 28.1 B | USA |
 |
Zhongchao
ZCMD
|
22.6 M | $ 2.13 | -1.39 % | $ 7.28 M | China |